The active pain pipeline is populated by 796 products across all stages of development, which exhibit a highly diverse range of molecular targets. GBI Research’s analyses identified 122 first-in-class programs in active development, constituting 13.6% of the pipeline and acting on 65 first-in-class molecular targets, indicating a high degree of innovation.

The antibiotics pipeline is very active, with 741 products in development. Of these, the majority (85%) are at the Discovery or Preclinical stages and have not yet entered human trials. Such a high proportion of drugs at the earliest stages of development would, in other indications, provide hope of a steady stream of drugs due to advance through the stages of development and be approved within the next decade.

The Global Irbesartan Industry Report 2015 is a professional and in-depth study on the current state of the Irbesartan industry.

The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Irbesartan market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.